Subscribe
shutterstock_706912843_adragan
adragan / Shutterstock.com
4 March 2019Big Pharma

CMA accuses hydrocortisone suppliers of anti-competitive behaviour

The UK Competition and Markets Authority (CMA) has provisionally found that pharmaceutical companies  Auden Mckenzie and  Waymade engaged in anti-competitive behaviour relating to hydrocortisone tablets.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
NHS to receive £8m from Aspen over anti-competitive practices
15 August 2019   Drugmaker Aspen has offered to pay the UK’s National Health System £8 million to resolve competition concerns.
Big Pharma
Phenytoin judgment will help clarify unfair pricing tests, says UK’s CMA
12 March 2020   The UK Competition and Markets Authority has welcomed a Court of Appeal ruling allowing it to press ahead with cases against Pfizer and Flynn Pharma over the unfair pricing of an epilepsy treatment.
Europe
CMA fines drugmakers £260m for 10,000% price hike
15 July 2021   The UK’s Competition and Markets Authority has imposed fines of £260 million on drug companies for raising the price of life-saving hydrocortisone tablets by 10,000%.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Big Pharma
NHS to receive £8m from Aspen over anti-competitive practices
15 August 2019   Drugmaker Aspen has offered to pay the UK’s National Health System £8 million to resolve competition concerns.
Big Pharma
Phenytoin judgment will help clarify unfair pricing tests, says UK’s CMA
12 March 2020   The UK Competition and Markets Authority has welcomed a Court of Appeal ruling allowing it to press ahead with cases against Pfizer and Flynn Pharma over the unfair pricing of an epilepsy treatment.
Europe
CMA fines drugmakers £260m for 10,000% price hike
15 July 2021   The UK’s Competition and Markets Authority has imposed fines of £260 million on drug companies for raising the price of life-saving hydrocortisone tablets by 10,000%.

More on this story

Big Pharma
NHS to receive £8m from Aspen over anti-competitive practices
15 August 2019   Drugmaker Aspen has offered to pay the UK’s National Health System £8 million to resolve competition concerns.
Big Pharma
Phenytoin judgment will help clarify unfair pricing tests, says UK’s CMA
12 March 2020   The UK Competition and Markets Authority has welcomed a Court of Appeal ruling allowing it to press ahead with cases against Pfizer and Flynn Pharma over the unfair pricing of an epilepsy treatment.
Europe
CMA fines drugmakers £260m for 10,000% price hike
15 July 2021   The UK’s Competition and Markets Authority has imposed fines of £260 million on drug companies for raising the price of life-saving hydrocortisone tablets by 10,000%.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility